

1 UNITED STATES PATENT AND TRADEMARK OFFICE

2
3 BEFORE THE PATENT TRIAL AND APPEAL BOARD

4
5 MYLAN PHARMACEUTICALS INC., CELLTRION, INC., and
6 APOTEX, INC.,

7
8 Petitioners,

9
10 - vs. -

11
12 REGENERON PHARMACEUTICALS, INC.,

13
14 Patent Owner.

15
16 Case IPR2021-00881
17 Patent No. 9,254,338 B2

18
19 Wednesday, May 4, 2022

20
21 The videotaped Deposition of RICHARD
22 MANNING, PH.D., taken at the Law Offices of
23 Arnold & Porter Kaye Scholer LLP, 601
24 Massachusetts Avenue NW, Washington, DC,
25 beginning at 9:46 a.m., Eastern Standard Time,
before Ryan K. Black, a Registered Professional
Reporter, Certified Livenote Reporter and Notary
Public in and for the District of Columbia.

PORTIONS OF TRANSCRIPT DESIGNATED CONFIDENTIAL

Veritext Legal Solutions

www.veritext.com

888-391-3376

Page 2

1 APPEARANCES:

2 RAKOCZY MOLINO MAZZOCHI SIWIK LLP

3 BY: DEANNE M MAZZOCHI, ESQ - Via Zoom

4 JEFF MARX, ESQUIRE

5 6 West Hubbard Street

6 Suite 500

7 Chicago, Illinois 60654

8 312 527 2157

9 Dmazzochi@rmmlegal.com

10 jmarx@rmmlegal.com

11

12 Representing - Petitioners

13

14

15 ARNOLD & PORTER KAYE SCHOLER, LLP

16 BY: DAVID CAINE, ESQUIRE

17 3000 El Camino Real

18 Five Palo Alto Square

19 suite 500

20 Palo Alto, California 94306

21 650 319 4500

22 david.caine@arnoldporter.com

23 - and -

24 ARNOLD & PORTER KAYE SCHOLER, LLP

25 BY: MATTHEW M WILK, ESQUIRE

26 250 West 55th Street

27 New York, New York 10019

28 212 836 8000

29 matthew.wilk@arnoldporter.com

30

31 Representing - Patent Owner

32

33

34 ALSO PRESENT:

35 James Evans - Regeneron

36 Eileen Wu - Regeneron - Via Zoom

37 Vinny Lee - Mylan

38 Solomon Francis - Legal Videographer

Page 4

1 INDEX (Cont'd)

2 EXHIBIT DESCRIPTION PAGE

3 Manning 4 a document titled "Aetna Insurance

4 Clinical Policy Bulletin date last

5 review February 18th, 2022, titled

6 "Vascular Endothelial Growth Factor

7 Inhibitors for Ocular

8 Indications"197

9 Manning 5 complaint in Merck v. Teva 395 F3rd

10 1364 Fed Circuit 2005.....209

11 Manning 6 the current Eylea labeling.....219

12 Manning 7 hyperlink in the Eylea labeling..219

13 Manning 8 Article dated 9/20 Which Anti-VEGF

14 Do I Choose as First-Line

15 Therapy.....262

16 Manning 9 a document American Society of

17 Retina Specialists Preferences and

18 Trends, AKA PAT Survey, of 2013..270

19 Manning 10 the 2017 ASRS PAT Survey.....277

20 PREVIOUSLY MARKED EXHIBITS

21 EXHIBIT PAGE

22 2052.....8

23 2051.....17

24 1001.....30

25 2136.....37

Page 3

1 INDEX

2 TESTIMONY OF: RICHARD MANNING, PH.D PAGE

3 By Ms. Mazzochi.....8, 290

4 By Mr. Caine.....287

5

6 EXHIBITS

7 EXHIBIT DESCRIPTION PAGE

8 Manning 1 a document titled L36962 Medicare

9 Part A/B local coverage

10 determination (LCD) comments

11 summary, for First Coast

12 Service Options, Inc.....130

13 Manning 2 United States versus Regeneron

14 Complaint, Civil Action No.

15 20-11217, filed June 24, 2020....145

16 Manning 3 a document titled Horizon Healthcare

17 Services, Inc., et al., versus

18 Regeneron Pharmaceuticals, Inc.,

19 Defendant, filed April 4th,

20 2020.....185

21

22

23

24

25

Page 5

1 INDEX (Cont'd)

2 EXHIBIT PAGE

3 2150.....43

4 2149.....54

5 2138.....66

6 2197.....89

7 2278.....109

8 Do 4.....124

9 2186.....215

10 2189.....218

11 1024.....222

12 2019.....234

13 2196.....249

14

15

16

17

18

19

20

21

22

23

24

25

Page 6

1 THE VIDEOGRAPHER: Good morning. We're
2 going on the record at 9:46 a.m. on May 4th,
3 2022.

4 Please note that the microphones are
5 sensitive and may pick up whispering, private
6 conversations and cellular interference. Please
7 mute all phones at this time. Audio and video
8 recording will continue to take place unless all
9 parties agree to go off the record. This is
10 Media Unit Number 1 of the video-recorded
11 deposition of Dr. Richard Manning, taken in
12 the matter of Mylan Pharmaceuticals, Inc.,
13 petitioners, and Regeneron Pharmaceuticals, Inc.,
14 patent owner, filed in the United States Patent
15 and Trademark Office before the Patent and Trial
16 Appeal Board. Case Number IPR2021-00880 and
17 IPR2021-00881.

18 This deposition is being held at Arnold
19 & Porter Kaye Scholer, as well as remotely. My
20 name is Solomon Francis, with Veritext Legal
21 Solutions, and I'm the videographer. Our court
22 reporter today is Ryan Black, with Veritext Legal
23 Solutions.

24 At this time will counsel please state
25 their appearances and affiliations for the

Page 7

1 record.

2 MS. MAZZOCHI: Good morning. My name is
3 Deanne Mazzochi, from the law firm Rakoczy Molino
4 Mazzochi Siwik LLP. Also with me is Jeff Marx.
5 And I will be questioning the witness today on
6 behalf of the petitioners.

7 MR. CAINE: Good morning. David Caine,
8 with Arnold & Porter, on behalf of the patent
9 owner. With me today are Matthew Wilk, with
10 Arnold & Porter, and James Evans and Eileen Wu,
11 who's on the video conference from Regeneron.

12 Let me just note for the record I
13 believe that Dr. Manning has submitted a
14 declaration only in the '881 IPR proceeding.

15 MR. MARX: Oh, Ms. Mazzochi already
16 introduced myself. I'm Jeff Marx, on behalf of
17 the petitioners, from Rakoczy Molino Mazzochi
18 Siwik.

19 THE VIDEOGRAPHER: At this time will the
20 court reporter please swear in the witness and we
21 can proceed.

22 * * *

23 Whereupon --

24 RICHARD L. MANNING, PH.D.,
25 called to testify, having been first duly sworn

Page 8

1 or affirmed, was examined and testified
2 as follows:

3 * * *

4 THE REPORTER: Thank you.

5 THE VIDEOGRAPHER: Please proceed,
6 Counsel.

7 EXAMINATION

8 BY MS. MAZZOCHI:

9 Q. Thank you, Dr. Manning. Could you
10 please state your full name and address for the
11 record?

12 A. Richard L. Manning, 1007 Cottage Street
13 Southwest, in Vienna, Virginia 22180.

14 Q. And, Dr. Manning, you've been deposed
15 several times before. Yes?

16 A. Yes.

17 Q. Dr. Manning, let's get straight to it,
18 and I'd like you to take a look at a document
19 that's been marked in this case as Exhibit 2052.
20 And I'd like you to confirm that this is your
21 declaration submitted in this case.

22 (Previously marked Exhibit No. 2052 was
23 introduced.)

24 MS. MAZZOCHI: And so while Mr. Manning
25 -- or Dr. Manning is reviewing, I'll just note

Page 9

1 for the record we plan on marking any new
2 exhibits to the deposition as Manning Exhibit
3 with the exhibit number. Any previously marked
4 exhibits that have already been submitted in this
5 proceeding will use their existing exhibit
6 numbers.

7 Thank you.

8 BY MS. MAZZOCHI:

9 Q. All right. So, Dr. Manning, can you
10 confirm that Exhibit 2052 is your expert
11 declaration for this proceeding?

12 A. It does appear to be, yes.

13 Q. All right. If we could take a little
14 look at some of your background information. If
15 you could turn to Page 1 of your report, which is
16 at Page 007 of 289, and I believe it's Paragraph
17 3. Let me know when you're there.

18 THE REPORTER: Can we turn the volume up
19 on this?

20 THE WITNESS: I'm sorry. Paragraph 3?

21 MS. MAZZOCHI: Yep.

22 THE WITNESS: Okay. I'm there.

23 BY MS. MAZZOCHI:

24 Q. All right. It states that your career
25 included serving as -- at multinational

3 (Pages 6 - 9)

Veritext Legal Solutions

www.veritext.com

888-391-3376



Find authenticated court documents without watermarks at docketalarm.com.

Page 10

1 pharmaceutical companies including Merck and
2 Pfizer. Yes?
3 A. That's correct.
4 Q. All right. Did either of those years of
5 your career involve ophthalmic drugs or devices?
6 A. Not specifically, no. I mean --
7 Q. Okay. When you were at --
8 A. -- I didn't work --
9 Q. When you were --
10 A. Sorry.
11 Q. Sorry.
12 When you were at Merck or Pfizer, did
13 you work on any drugs targeting the retina?
14 A. Not that I recall, no.
15 Q. And let's talk about your time at Pfizer
16 that concluded in 2009. Where did you start at
17 Pfizer? Was it within Pfizer proper or a company
18 that was acquired into Pfizer?
19 A. I was hired into Pfizer from academics,
20 so I came into Pfizer directly from the outside.
21 Q. And when you were at Pfizer, what drug
22 compounds did you do work on?
23 A. Well, my role at Pfizer was not
24 typically product-specific. I mean, I would get
25 involved in questions that touched on specific

Page 11

1 drugs from time to time, but I was not on a
2 product team. I was a -- an economist at the
3 corporate -- in the corporate center, so my
4 responsibilities weren't very often or weren't
5 typically tied to a specific product issue.
6 Q. Then what exactly were you doing at
7 Pfizer?
8 A. I was, as I said, an economist in the
9 corporate center. I worked on a variety of
10 issues where, as it describes in my report, I led
11 economic analysis to shape the practices relating
12 to emerging business concerns. I would provide
13 input to senior executives on a variety of
14 business or -- or other external challenges that
15 were facing the company. I would interface with
16 outside academic economists and others who were
17 evaluating the economic situation that the
18 company and the industry faced; things associated
19 with intellectual property challenges, for
20 example, threats to intellectual property, in --
21 in the U.S. and abroad; questions about price
22 controls or questions about, both internationally
23 and domestically, the prospect of them; questions
24 about how marketing might be affected by either
25 regulatory or legislative actions that might

Page 12

1 have been contemplated; questions about payment
2 policies; questions about financing for
3 healthcare.
4 I could go on. I think I've summarized
5 those in my report, though, and I guess I
6 would --
7 Q. So was your role -- yeah. So just so I
8 have a sense, was your role more of a public
9 policy-type role where you were trying to drive
10 and influence policy or were -- well, I'll just
11 stop with that.
12 A. My -- I was in the corporate strategic
13 planning and policy department or division.
14 That was a small division at the corporate center
15 where we would not directly affect policy, but
16 analyze the environment, which included the
17 policy environment, but also included the payor
18 environment or the business environment as it was
19 evolving. So I was not a lobbyist. Although I
20 would work on occasion with the Washington
21 office, that was not my primary responsibility.
22 Q. Okay. Were -- did you ever do any con
23 -- any analyses in connection with off-label use
24 promotions of any Pfizer drugs, or off-label
25 promotions, in general?

Page 13

1 A. Well, I guess I'm hanging up on the
2 question of "analysis." I mean, certainly,
3 off-label utilization was something that we
4 talked about or I -- I had work about. But I
5 wouldn't -- unless you were more specific about
6 the question, I don't know that I could really
7 give you an answer.
8 Q. Okay. Well, during your time at Pfizer,
9 was that at around the time when there was a huge
10 criminal complaint filed with Pfizer, as well as
11 a large civil settlement, in connection with
12 off-label promotions?
13 A. There was a -- I don't remember the
14 exact timing of it, and I was not directly
15 involved in it -- that, but I do remember there
16 being a large settlement in a case like that,
17 yes. I don't remember the exact timing of it.
18 Q. Did you do any economic analyses
19 in connection with what was ultimately the
20 settlement that Pfizer did with the federal
21 government?
22 A. No.
23 Q. Were you involved in any efforts to try
24 to improve Pfizer's corporate compliance plans in
25 connection with that criminal and civil charge?

Page 14

1 A. No.
2 THE WITNESS: Sorry. But I -- I'd like
3 to tell the videographer that there's something
4 on the screen that --
5 MR. CAINE: Yeah. Maybe we could just
6 dismiss that.
7 BY MS. MAZZOCHI:
8 Q. Let's go ahead and go to Page 3 of your
9 Expert Declaration, Exhibit 2052. Paragraph 8.
10 THE REPORTER: You're cutting out.
11 MS. MAZZOCHI: Sorry. Let me try that
12 again.
13 BY MS. MAZZOCHI:
14 Q. Turn to Page 3 of Exhibit 2052, your
15 expert declaration, Page 009 of 289, specifically
16 Paragraph 8.
17 A. Okay.
18 Q. It states you're being compensated at
19 your standard hourly rate. What is that rate?
20 A. \$950 per hour.
21 Q. Okay.
22 A. To be --
23 Q. And how many --
24 A. To be clear, Intensity, the firm, is
25 being compensated at that rate.

Page 15

1 Q. Right. And how many others worked on
2 this -- at the firm worked on this project with
3 you?
4 A. Two staff members, primarily. There are
5 two others that I know worked a fair amount, and
6 then probably a couple of others in some of the,
7 you know, document preparation.
8 Q. Okay. And who are the two staff members
9 you primarily worked with?
10 A. Ryan Marsh, who's a Ph.D from
11 Northwestern University, was the man -- project
12 manager. Max Urman, and I'm actually not sure
13 how to spell his last name, but he was one of the
14 lead consultants. The two others I have in mind
15 at this moment -- and I may not remember
16 everybody, I'm sorry -- were Elizabeth Parker and
17 Arvin Mohapatra.
18 Q. And what -- what did you ask Mr. Urman
19 to do in connection with the preparation of this
20 declaration?
21 A. Well, there were a variety of things
22 that were done to prepare for and execute the
23 declaration. We looked at data, we looked at
24 large number of data sets or -- or presentations
25 that were provided to organize the work, to think

Page 16

1 about what the key questions were and to bring
2 the analyses into a form so the -- I don't know
3 exactly who did this, but, as you see, the attach
4 -- the attachments to the declaration had to be
5 processed and put into that, things like that, to
6 generate the -- the information that is included
7 in those attachments.
8 Q. Okay. And what did Ryan Marsh do in
9 connection with the preparation of your
10 declaration?
11 A. Ryan was the project manager. As I
12 mentioned, he's also a Ph.D economist, so he and
13 I -- he and I talked very frequently about my
14 view of what the questions -- key questions were,
15 what I wanted him to evaluate, what I wanted the
16 team to explore, and then we talked about what
17 the findings implied and what -- what -- what --
18 how they fit into what I can -- ultimately came
19 to as my opinion on the matter.
20 Q. In connection with preparing what -- you
21 know, some of these documents that are cited in
22 your expert report, did you prepare any Excel
23 spreadsheets?
24 A. Yes. I'm sure there -- in fact, I think
25 all of the attachments that were here are in some

Page 17

1 form in an Excel spreadsheet.
2 Q. Okay. Did you produce the native
3 forms of those or just paper copies with your
4 declaration?
5 A. To tell you the truth, I'm not sure.
6 Q. Do you still have the original Excel
7 spreadsheets in native form?
8 A. Not on me today, no. I -- but if -- but
9 if we did, they would be on my firm's network.
10 Q. Okay. Well, we'll ask that those be
11 looked for and produced.
12 Do you know approximately how much your
13 firm has billed Regeneron to date?
14 A. Approximately?
15 Q. Yeah.
16 A. \$500,000, more or less. I'm not sure.
17 (Previously marked Exhibit No. 2051 was
18 introduced.)
19 BY MS. MAZZOCHI:
20 Q. If you take a look at Page 4 of your
21 declaration, Paragraph 11, which is Exhibit 2051
22 [sic] Page 10 of 289, it states that interviews
23 were conducted with some Regeneron people. Why
24 did -- did you ask to conduct these interviews or
25 were they simply offered to you?

5 (Pages 14 - 17)

Veritext Legal Solutions

www.veritext.com

888-391-3376



Find authenticated court documents without watermarks at docketalarm.com.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.